



RESEARCH for
A **cure**

NATIONAL FOUNDATION FOR CANCER RESEARCH
2005 PROGRESS REPORT

The Mission

The National Foundation for Cancer Research (NFCR) was founded in 1973 to support cancer research and public education relating to the prevention, early diagnosis, better treatments and ultimately, a cure for cancer. NFCR promotes and facilitates collaboration among scientists to accelerate the pace of discovery from bench to bedside. NFCR is committed to *Research for a Cure* — cures for all types of cancers.

Table of Contents

President’s Message	1
Turning Off Cancer: Dr. Harold Dvorak	2
NFCR Scientists	4
Nanotechnology and Targeting Wayward Cancer Cells: Dr Esther Chang	7
Scientific Conferences and Collaborations	8
Joining Together to Make a Difference	9
Working Together to Fight Cancer	10
Screensaver-Lifesaver: Pancreatic Cancer—Latest Target	11
Making a Difference	12
One Family’s Effort to “Wipe Out” Cancer: Wayne Miyata	13
Financials	14
Contributors to a Cure	16

President's Message

We are at a turning point in the battle against cancer, and doctors are genuinely excited about a new generation of anti-cancer drugs — specialized treatments, known as targeted cancer therapies. Targeted cancer therapies are anti-cancer drugs that hone in on the molecular characteristics of cancer cells, leaving healthy tissue (that is often damaged by standard treatments like radiation and chemotherapy) relatively unharmed.

Because targeted therapies potentially target cancer cells while sparing healthy cells, there is great hope for targeted therapies as a new and more effective way to treat cancers with fewer side effects.



*NFCR President Franklin C. Salisbury, Jr. and
NFCR Project Director Dr. Daniel Haber at
Massachusetts General Hospital Cancer Center.*

"I feel lucky...NFCR made a difference in saving my life"

NFCR's cancer research, in order to better understand cancer cells at the molecular level, has led to new, targeted treatments for cancer patients. More and more cancer patients are thankful for these breakthroughs in cancer treatments. In 2003, one such patient, an attorney in Glenridge, NJ, was diagnosed with pancreatic cancer and given a slim chance of survival. But he sought treatment at the NFCR Center for Targeted Cancer Therapies where co-director Daniel Von Hoff prescribed the anti-cancer drug Tarceva®, and he responded well. Through it all he told me, "I feel lucky...NFCR made a difference in saving my life."

Basic science research is essential to drug development—the more we understand the mechanisms by which cancer grows and multiplies, the greater impact NFCR is going to have. **Research for a Cure**...it's about saving lives.

Sincerely,


Franklin C. Salisbury, Jr.
President

Turning Off Cancer

Dr. Harold Dvorak: Changing the Face of Cancer Research



NFCR Fellow Dr. Harold Dvorak, Harvard Medical School and Beth Israel Deaconess Medical Center. (Above) and an Illustration of VEGF (right) courtesy of Genentech, Inc.



Dr. Dvorak's discovery of the vascular endothelial growth factor (VEGF) and its critical role in tumor angiogenesis was a pivotal breakthrough, providing a fundamental explanation of how tumors induce new blood vessel growth. His research helps explain how the blood vessels of malignant tumors differ from those of normal tissue with respect to organization, structure, and function¹.

VEGF is the primary target for therapies designed to stop angiogenesis in the treatment of cancer. Angiogenesis inhibitors that target VEGF are now approved by the FDA in the United States for the treatment of cancer and macular degeneration, and have received approval in 27 other countries. Antibodies against VEGF have improved the survival of patients with advanced colorectal and lung cancer. Most anti-angiogenesis cancer drugs available today are based on Dr. Dvorak's NFCR-funded research.

Former Beth Israel Deaconess Medical Center President, Dr. Mitchell Rabkin hails Dr. Dvorak's VEGF research as one of the major intellectual accomplishments to ever come out of Harvard. "Without Dr. Dvorak's fundamental discovery, we would probably not have had the therapeutic agent *bevacizumab* which has had a tremendous impact on improving survival for patients with advanced colorectal cancer,

breast cancer, non-small cell lung cancer and renal cell carcinoma," adds Dr. Daniel Von Hoff, co-director of the NFCR Center for Targeted Cancer Therapies and Vice President of the Translational Genomics Research Institute in Phoenix.

¹VEGF was discovered in 1983 by Dr. Harold Dvorak and colleagues as a factor that made blood vessels leaky; hence, it was given the name of vascular permeability factor (VPF). Senger, D. R. *et al.* Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. **Science** **219**, 983-985 (1983). Then, in the late 1980s, several groups showed that VEGF/VPF stimulated endothelial cell migration and replication and was a potent angiogenic factor in vivo.


Turning Off Cancer *(continued)*

The anti-cancer drug Avastin® (*bevacizumab*) was the first anti-angiogenesis drug to be approved by the FDA for the treatment of advanced colorectal cancer. Avastin is a monoclonal antibody that can bind to the VEGF protein, render it inactive, and thereby shut down the hungry tumor cells' ability to stimulate blood vessel growth. This essentially starves the tumor and helps prevent the cancer from spreading. When Avastin is combined with conventional chemotherapy, it impedes tumor growth sufficiently to provide the chemotherapy with an improved chance to destroy the cancer cells.

Arthur D. Levinson, Ph.D., Chairman and Chief Executive Officer of Genentech, Inc., the maker of Avastin, adds that "this anti-angiogenic drug marks an important shift in the treatment of metastatic colorectal cancer, with the approval of an innovative treatment based on elegant science that targets cancer in an entirely new way."

After decades of supporting basic science cancer research in the laboratory, research funded by NCFR offers cancer patients hope for angiogenesis-centered treatments that will stop tumor growth.

As one discovery leads to another, a new frontier in targeted cancer therapies has been found to develop and improve existing drugs to achieve their maximum therapeutic effects. Cancer treatment will never be the same again.



The role of VEGF to a blood vessel. Illustration courtesy of Genentech, Inc.

"Without Dr. Dvorak's fundamental discovery, we would probably not have had...a tremendous impact on improving survival for patients with advanced colorectal cancer, breast cancer, non-small cell lung cancer, and renal cell carcinoma."

— Daniel Von Hoff, M.D., FACS,
Co-director of the NCFR Center
for Targeted Cancer Therapies



Daniel Von Hoff, M.D.
NFCR Center for Targeted
Cancer Therapies



Alanna Schepartz, Ph.D.
NFCR Center for Protein
and Nucleic Acid Chemistry



Wayne A. Marasco, M.D., Ph.D.
NFCR Center for Therapeutic
Antibody Engineering

Progress in understanding cancer through molecular science is the key to finding a cure for this devastating disease. NFCR's breakthrough discoveries are leading to better cancer treatments and ultimately, a cure for this disease. With 15 Project Directors, 10 Fellows, and 9 Research Discovery Centers from across the globe, NFCR scientists are taking novel approaches, and sharing ideas that are bringing hope to cancer patients every day.

Research Discovery Centers

NFCR Center for Computational Drug Discovery

University of Oxford, Oxford, UK
W. Graham Richards, D.Sc.

The Center is creating a database for drug screening by using computer software to identify new protein targets leading to novel anti-cancer drugs and cancer prevention techniques.

NFCR Center for Genomics and Nutrition

University of California, Berkeley, CA
Children's Hospital Oakland Research Institutes, Oakland, CA
Bruce N. Ames, Ph.D.
Martyn T. Smith, Ph.D.

The Center is focusing to lower cancer risk through understanding the interaction between nutrition and genetics.

NFCR Center for Metastasis Research

University of Alabama
Penn State University
University of Chicago
Danny R. Welch, Ph.D.

The Center is identifying and targeting the fundamental molecular changes in cancer cells that allow them to metastasize and translate these basic research findings into strategies to prevent metastasis and/or treat patients who have metastatic cancer of the breast, prostate, and metastatic melanoma.

NFCR Center For Molecular Oncology

Institute of Medicinal Biotechnology, Beijing, China
Jian-Dong Jiang, M.D., Ph.D.

The Center is focusing on a new generation of anti-cancer drugs by studying cell cycle regulatory mechanisms.

NFCR Center for Molecular Analysis and Imaging

Massachusetts General Hospital, Boston, MA
Ralph Weissleder, M.D., Ph.D.
James P. Bacion, Ph.D.

The Center is using molecular imaging to devise new and improved methods for early cancer detection and treatment.

NFCR Center for Targeted Cancer Therapies

Arizona Cancer Center, Tucson, AZ
Daniel D. Von Hoff, M.D.
Laurence Hurley, Ph.D.

The Center is focusing on identifying, designing, and evaluating uPA inhibitors to develop new anti-cancer agents to improve pancreatic cancer treatments.

NFCR Center for Protein and Nucleic Acid Chemistry

Yale University, New Haven, CT
Alanna Schepartz, Ph.D.
Don Crothers, Ph.D.

The Center is analyzing the conformations, structures, and interaction kinetics of proteins and nucleic acids critical to the development of cancer to lead to the foundation for novel approaches to fight cancer.

NFCR Center for RNA Cancer Research

Freie Universität Berlin, Germany
Volker A. Erdman, Ph.D.

The Center is developing a novel technique, "micro surgery method" that can be utilized to eliminate mRNAs crucial in the progression of cell transformation.

NFCR Center for Therapeutic Antibody Engineering

Dana-Farber Cancer Institute, Cambridge, MA
Harvard Medical School
Wayne A. Marasco, M.D., Ph.D.

The Center is identifying high affinity human sFvs to virtually any cancer target of interest, including oncoproteins of human origin and proteins that are involved in cancer causing signaling pathways.



NFCR founded by Nobel-prize winner Dr. Albert-Szent Györgyi and entrepreneur Franklin C. Salisbury.



Dr. Laszlo Muszbek discovers the role of transglutaminase which prevents cancer cell proliferation.



Dr. Mario Dianzani links the role of lipid peroxidation and aldehydes in liver cancer development.

1973

1975

NFCR Fellows

Webster Cavenee, Ph.D.

*Ludwig Institute for Cancer Research,
San Diego, CA*

Cavenee is identifying genes whose mutation or altered expression leads to malignant tumors of the brain and muscle.

Yung-Chi Cheng, Ph.D.

*Yale University School of Medicine,
New Haven, CT*

Cheng is exploring a Chinese medicinal formula discovered to decrease hematological side effects and enhance anti-tumor activity for a variety of anti-cancer drugs.

Curt I. Civin, M.D.

Johns Hopkins University, Baltimore, MD

Civin is researching how the survival, proliferation, and differentiation of normal and malignant leukemia cells are regulated, and translating the results into useful clinical tools.

Stanley N. Cohen, M.D.

*Stanford University School of Medicine,
Stanford, CA*

Cohen is researching the elucidation of the genetic control of tumorigenesis and cancer metastasis.

Harold F. Dvorak, M.D.

*Beth Israel Deaconess Medical Center,
Boston, MA*

Dvorak is elucidating the steps and mechanisms of tumor angiogenesis and contrasting these with the steps and mechanisms by which normal blood vessels form.

Waun Ki Hong, M.D.

M.D. Anderson Cancer Center, Houston, TX

Hong is studying the drug celecoxib (Celebrex™) in a clinical trial for the chemoprevention of lung cancer.

Susan Band Horwitz, Ph.D.

Albert Einstein College of Medicine, Bronx, NY

Horwitz is searching for natural products that are analogues of Taxol® that circumvent the problem of tumor multi-drug resistance.

Paul Schimmel, Ph.D.

Scripps Research Institute, La Jolla, CA

Schimmel is understanding how components of the genetic code function in signal transduction pathways in ways that can be used to treat cancers.

Helmut Sies, M.D., Ph.D.

Heinrich-Heine-Universität, Germany

Sies is addressing the underlying mechanism and biological impact of DNA damage related to ultraviolet radiation that give rise to skin cancer, and the defense systems repairing such damage.

I. Bernard Weinstein, M.D.

Columbia University, New York City, NY

Weinstein is exploring abnormalities in the circuitry that controls cell cycle progression and signal transduction in cancer cells, and using these insights to develop naturally occurring and synthetic compounds that can be used in cancer prevention and therapy.

NFCR Project Directors

Rebecca W. Alexander, Ph.D.

Wake Forest University, Winston-Salem, NC

Alexander is understanding protein-nucleic acid interactions that are fundamental to cellular processes in both normal and tumor cells.


Jacqueline Barton, Ph.D.

California Institute of Technology, Pasadena, CA


Barton is researching the consequences of DNA charge transport chemistry with respect to how DNA is damaged and repaired.



Waun Ki Hong, M.D.
M.D. Anderson Cancer
Center, Houston, TX



Susan Band Horwitz, Ph.D.
Albert Einstein College of
Medicine, Bronx, NY



I. Bernard Weinstein, M.D.
Columbia University,
New York City, NY



Dr. Gabor Fodor synthesizes ascorbic acid (vitamin C) derivatives which combats cancer.



Dr. Harold Dvorak discovers vascular endothelial growth factor (VEGF) which is the foundation for many anti-cancer drugs.

1980



Dr. Thomas Merigan discovers ways to treat lymphoma with interferons and monoclonal antibodies.



Robert Bast, Jr., M.D.
M.D. Anderson Cancer
Center, Houston, TX

Robert Bast, Jr., M.D.

M.D. Anderson Cancer Center, Houston, TX
Bast is identifying novel tumor suppressor genes in epithelial ovarian cancer.

Joseph R. Bertino, M.D.

*The Cancer Institute of New Jersey,
New Brunswick, NJ*
Bertino is determining if sequential administration of a low dose of flavopiridol, a cyclin dependent kinase inhibitor, can sensitize small cell lung cancer cells to another drug, doxorubicin.

Esther H. Chang, Ph.D.

Georgetown University, Washington, DC
Chang is exploring chemosensitization of breast cancer cells by systemic delivery of anti-HER2 oligonucleotides.

Laurence J.N. Cooper, M.D., Ph.D.

*City of Hope National Medical Center,
Duarte, CA*
Cooper is evaluating the anti-lymphoma effects of combining CD19-specific human white blood cells, with CD20-specific immunocytokines.

Donald M. Engelman, Ph.D.

Yale University, New Haven, CT
Engelman is researching the possible roles of membrane helix interactions in viral carcinogenesis.

Daniel A. Haber, M.D., Ph.D.

*Massachusetts General Hospital Cancer Center,
Charlestown, MA*
Haber is discovering new tumor suppressor genes implicated in cancer progression using Representational Difference Analysis.

Kathryn Horwitz, Ph.D.

*University of Colorado Health Science Center,
Denver, CO*
Horwitz is understanding the role of estrogen, progesterone, and their receptors in breast cancer.

John G. Koland, Ph.D.

University of Iowa, Iowa City, IA
Koland is understanding the impact of epidermal growth factor receptors on the disease process and therapeutic strategies for breast cancer.

Janos Ladik, Ph.D.

Universität Erlangen-Nurnberg, Erlangen, Germany
Ladik is investigating the cancer prevention effects of DNA intercalating agents.

Lawrence J. Marnett, Ph.D.

*Vanderbilt University Medical Center,
Nashville, TN*
Marnett is understanding the role of endocannabinoids on the growth and differentiation of colon carcinoma cells as well as normal keratinocytes.

Terence H. Rabbitts, Ph.D.

*MRC Laboratory of Molecular Biology,
Cambridge, England*
Rabbitts is developing anti-RAS intrabodies as anti-cancer reagents, which can block cancer cell growth, invasion, or metastasis *in vivo*.

Alan C. Sartorelli, Ph.D.

*Yale University School of Medicine,
New Haven, CT*
Sartorelli is understanding the role of the transcription factor Scl in sensitivity of leukemia cells to all-trans retinoic acid induced differentiation.

Michael Sporn, M.D.

Dartmouth Medical School, Hanover, NH
Sporn is developing new triterpenoid compounds for the prevention of cancer through their anti-proliferative and anti-inflammatory properties.



Joseph R. Bertino, M.D.
The Cancer Institute of New
Jersey, New Brunswick, NJ



Michael Sporn, M.D.
Dartmouth Medical
School, Hanover, NH



Dr. Clive Evans discovers how cancer cells spread through the functions of adhesion molecules.



Dr. Norman Krinsky uses potent antioxidants from carotenoids and retinoids as anticarcinogenic agents.



Dr. Anton Stier pioneers retroviral oncogenes research related to cancer cell development.



Nanotechnology and Targeting Wayward Cancer Cells

Imagine small “ambulances” that travel through the body, find cancer cells, and deliver their targeted cancer therapies directly to a patient’s cancer—both to the tumor and to those cancer cells that have metastasized.

—Sujuan Ba, Ph.D., NFCR Chief Scientific Officer

For someone with cancer there is no greater fear than learning one’s cancer has spread.

NFCR has long supported Dr. Esther Chang and her research to find new therapies to combat deadly cancer tumors that are metastasizing to secondary locations.

Dr. Chang is another NFCR scientist pioneering research to deploy targeted cancer therapies which use a “laser beam” instead of a “shotgun” approach to target the cellular switches that make cancers grow.

But many issues still need to be addressed before the promise of tumor-targeting diagnosis and therapy for cancer can be realized. Foremost amongst these is the efficient and selective delivery of diagnostic or therapeutic molecules to the site(s) in the body where the target tumor cells reside. Of particular relevance to cancer is the ability to target cells that have migrated via metastasis from the site of the primary tumor.

To meet this challenge Dr. Chang’s laboratory has demonstrated that a systemically administered, cationic liposomal nanocomplex bearing molecules that home to the surface of tumor cells can efficiently and selectively deliver diagnostic contrast agents and targeted cancer therapies to primary tumors and metastases in a variety of human cancers.

The secret of this nanotechnology drug delivery system lies in a liposome nanoparticle, roughly one millionth of an inch across, pinned with antibodies that can zoom in on tumor cells wherever they spread in the body. The liposome encapsulates the p53 gene by binding to its transferring receptors in order to restore its normal activity.

Dr. Chang’s targeted cancer therapy has now entered into a Phase I study at the Georgetown University Medical Center. Twenty patients are currently enrolled with advanced solid tumors, including head and neck, prostate, pancreatic, breast, bladder, colon, cervical, brain, melanoma, and lung cancers.

For more information about Dr. Chang and the progress of her clinical trial, visit www.NFCR.org.



NFCR Project Director Dr. Esther Chang, Georgetown University (above), and Dr. Esther Chang and Dr. Harold Dvorak (left)



Dr. Csaba Horvath expands the method for identifying and quantifying biopolymers, HPLC, which today, pharmaceutical companies use to develop new drugs.



Dr. Jack Gorski modifies estrogen receptor activities. This is the foundation for hormone therapy.



Dr. Anthony Pegg alters polyamine levels in kidney cancer cells increasing responsiveness to chemotherapy.

Biofunding Summit 2004: Targeted Therapies, A New Paradigm for Treating Cancer



Richard Mallery, Chairman and CEO, International Genomics Consortium, and Dick Love, Managing Director, TGen Accelerators, LLC.



Cancer is an individualized disease and each person responds in unique ways to cancer treatments and cancer therapies. NFCR is investing in research and encouraging physicians to look deeper into methods that explore the interactions of treatments at the genetic level, through targeted therapies.

To achieve this goal, NFCR invited researchers from across the globe to the *Biofunding Summit: Targeted Therapies, a New Paradigm for Treating Cancer* in La Jolla, California.

Co-hosted by the Burnham Institute, International Genomics Consortium and the Translational Genomics Institute, this three-day conference highlighted current breakthrough research in cancer research and treatments in the areas of individualized medicine and targeted cancer therapy treatments. The conference also provided a forum for researchers to share and exchange novel ideas that will accelerate the pace for new treatments to cancer patients.

The keynote address presented by Colin Goddard, Ph.D., CEO of OSI Pharmaceutical, announced that clinical trial results showed that combining two new anti-cancer drugs, Avastin® and Tarceva®, provided a “one-two punch” against the nation’s leading cancer killer, Non-Small Cell Lung Cancer (NSCLC). Co-Director of the NFCR Center for Targeted Therapies in Phoenix, Arizona, Daniel Van Hoff, Ph.D., credited the support of NFCR for the funding of this successful targeted therapy approach.

Because of these types of breakthrough discoveries, targeted therapies are helping to save lives all over the world. The continued investment in research means targeted therapies will soon provide doctors a better way to treat cancer with individualized cancer treatments while harming fewer normal cells, reducing side effects, and improving the quality of life for all cancer patients.

Creating a Global Research Network



NFCR President Franklin C. Salisbury, Jr. and Dr. Xi-Shan Hao, President, Tianjin Cancer Institute (above)

NFCR and the Tianjin Cancer Institute and Hospital (TCIH) have joined forces to expand the NFCR international research program into China and all across Asia. This unique partnership supports NFCR’s commitment to promoting collaborative cancer research programs, by providing a comprehensive cancer database that will lead to the development of novel therapy strategies with better and more accurate targets.

TCIH, affiliated with the Tianjin Medical University, is one of the oldest cancer specialty hospitals in China and is noted as the premier center for cancer prevention, treatment, and research. TCIH has established strong comprehensive clinical and research programs in oncological surgery, bio-therapy, cancer prevention, pathology, and epidemiology and is the home of the Chinese Anti-Cancer Society as well as its Tianjin branch.

Establishing this joint international collaborative partnership is a critical link in our ongoing innovative cancer research program—one that is designed to accelerate the pace to finding a cure for all types of cancers.



Dr. Garth Nicholson characterizes heparanases, providing a promising approach to stop the spread of cancer.



Dr. Leonard Rosenthal discovers how cytomegalovirus (HCMV) results in Kaposi’s sarcoma associated with AIDS.



Dr. Colin Thomson utilizes a supercomputer to calculate the 3-D structures of cancer cells for drug-protein interaction.



Joining Together to Make a Difference

1.3 million donors and supporters worldwide are the foundation of NFCR.

In 2005, many dedicated supporters took action with special events across the nation to help raise funds in support of NFCR's cutting-edge cancer research programs.

Sharing in the Fight

TV News Anchor, Sam Donaldson, joined women across the Washington, DC metropolitan area for the annual *Daffodils and Diamonds* luncheon. Over 400 women showed their support by raising over \$35,000 that will help find cures for breast and ovarian cancers.

Spreading the Support Against Cancer

Master Magician Yun Xing Yang amazed pre-schoolers, teenagers and adults with jaw-dropping magic that captivated audiences. The mystifying magic not only dazzled everyone but also brought together NFCR supporters and their families to share in their support of the fight against cancer.

Continuing to Make a Difference

The 6th Annual *Hazleton Golf for a Cure Classic*, one of NFCR's signature events, was hosted by Karchner Logistics and Distribution Services. Over the years, this event and the support of the Hazleton, PA community has raised more than \$50,000 to help fight cancer.

Teeing Off for Cancer

The 3rd Annual *DC Golf for a Cure Classic* brought donors and corporations together sharing a beautiful day of golf to support the fight against cancer. Local golfers and corporations, such as Merrill Lynch, M&T Bank, Vocus, Legg Mason, and many more, gathered in the annual event to help raise funds for NFCR's cancer research programs that will defeat cancer.



Daffodils and Diamonds, 2005 Luncheon—NFCR Supporters Tara Fettig Ryan, Sam Donaldson, and Carole Fettig (above); Magic for a Cure 2005 master magician Yun Xing Yang (left); Hazleton Golf for A Cure Classic – NFCR Supporters Dave Conway and Bob Duffy of Toyota Industrial Lift Truck Company (below).



Hazleton Golf for a Cure Classic – NFCR supporter Bob Luchi of Karchner Logistics and Distribution Services.

Make a difference by creating an outreach event or activity to help raise funding for NFCR's breakthrough cancer research programs by calling us today at 1-800-321-CURE (2873).



Dr. Esther Chang demonstrates that anti-HER-2 antisense ODN (AS-HER-2 ODN) treatment sensitizes breast cancer cells to various chemotherapies.



Dr. Bert Vogelstein develops advanced colon cancer diagnostic test which detects colon cancer suppressor gene APC.

1990



Dr. Kathryn Horwitz discovers progesterone receptors in breast cancer and using this to develop new breast cancer diagnostic tests.

Working Together to Fight Cancer

NFCR is dedicated to establishing new, collaborative programs to continue the fight against all types of cancers. Through these NFCR partnerships, supporters can contribute to NFCR's life-saving cancer research programs. To learn more, visit our website at www.NFCR.org.



American Airlines—Serving over 250 cities around the world, American Airlines® is the largest airline in the world. Through the NFCR AAAdvantage® Members partnership, donations are turned into airline miles. For every \$25 donated to NFCR, you can earn 10 AAAdvantage miles.



Teleflora Flower Club—In 2004 Teleflora, the world's largest fresh cut flower provider, partnered with NFCR to positively impact the lives of those affected by cancer. Together, Teleflora and NFCR created a program that allows 20% of all floral purchases to go toward supporting the initiatives of NFCR. Teleflora is excited to have the opportunity to support cancer research and education to support NFCR.



CancerConsultants—In-depth cancer specific prevention, treatment, news, and information are critical to those suffering from cancer, as well as those who care for them. NFCR and CancerConsultants have partnered to provide the most current, up-to-date cancer information available in the free newsletter, SURVIVE!



Seeds of Hope—The "Seeds of Hope" classic jewelry pin was designed exclusively for NFCR by renowned jewelry artists Angela Deane and Robert Coogan. Each pin acts as a symbol of daily dedication to the fight against cancer and reminds us how every seed of hope can make a difference. 10% of the proceeds of the sale of each pin supports NFCR's life-saving cancer research programs.



YTB Travel International—YTB Travel International, a leading provider of travel services over the Internet, has partnered with NFCR to provide the best discounted travel rates available and allow you to donate to a great cause. When you book your personal and business travel at www.CauseTravel.com, up to 8% of your purchase is donated to NFCR to fund cancer research programs that will lead to a cure for cancer.



Esquire Magazine—Esquire Magazine has partnered with NFCR in the fight against cancer. Esquire is not only donating 50% of each paid subscription but it is the only magazine for sophisticated men that contains editorial coverage ranging from superb style and award-winning journalism to outdoor adventure, technology, and indelible humor.



Ondrox—Ondrox™ is a dietary supplement packed with antioxidants, vitamins, and minerals that may help slow or possibly prevent the development of cancers. Ondrox is a patented supplement specifically designed to provide the best results in controlling free radical damage. The product, however, has not been approved by the Food and Drug Administration and is not intended to prevent, diagnose, mitigate, treat, or cure a disease (cancer).



Dr. Cesar Milstein defines DNA elements in the control of hypermutation, an integral part of constructing monoclonal antibody applications.



Dr. Janos Ladik begins research on long-term carcinogenic effects of nonlinear wave, or soliton, to prevent cancer progression.



Dr. Wayne Marasco develops intracellular antibodies (sFv), or intrabodies, which slows cancer progression.

1995

Screensaver-Lifesaver: Pancreatic Cancer—Latest Target

Pancreatic cancer is the fourth leading cause of cancer deaths in the United States and has the lowest survival rates of all types of malignancies. The one-year survival rate for pancreatic cancer patients is just 24%, and only 4% will survive after five years.

Currently, available treatment options for pancreatic cancer are very limited. The process for pancreatic cancer drug development must be accelerated for pancreatic cancer patients who simply do not have time to wait the 15 years or more it takes for drugs to go through the development process.

Since 1973, NFCR has been a catalyst for synergistic collaborations between cancer researchers worldwide. When scientists make an initial discovery, we proactively connect them with other researchers who can help bring that discovery from the lab to the patient's bedside as quickly as possible.

Recently, Center Co-Directors Dr. Daniel Von Hoff and Dr. Laurence Hurley at the NFCR Center for Targeted Cancer Therapies at the University of Arizona identified new protein targets that are related to the development of pancreatic cancer including Aurora A Kinase and PRL-1 Phosphatase.


To develop new drugs targeting these cancer proteins, Drs. Von Hoff and Hurley need to be able to screen molecules that can specifically bind and block the cancer-causing activities of these proteins; they need strong collaborators who can provide expertise in drug screening.

Dr. Graham Richards, Director of the NFCR Center for Computational Drug Discovery at the University of Oxford, is a pioneer in computational drug discovery. He and his team have developed the capability to utilize the GRID computing technology platform to screen billions of small molecules against protein targets relevant to various types of cancer.

Through the help of more than 3 million individual computer users around the world, this NFCR Research Center has created the biggest virtual supercomputer in existence today. The powerful virtual screening capability of the supercomputer can perform more than 50 trillion operations per second, greatly reducing the time it takes for new drug development.

Dr. Richards is a perfect collaborator for Drs. Von Hoff and Hurley to bring new hope to pancreatic cancer patients.

NFCR has committed additional funding to enable these two research centers to work together, in an effort to save more lives, more quickly.



Join our fight against pancreatic cancer and all other types of cancers by downloading the free screensaver-lifesaver at www.NFCR.org.



Dr. Bruce Ames reveals the role of Vitamins B12 and folic acid in preventing DNA damage.




Dr. Daniel Von Hoff reveals aurora kinase inhibitor and urokinase-type plasminogen activator pathways to develop pancreatic cancer drugs.



Dr. Helmut Sies discovers that lycopenes, the red pigment found in tomatoes, provide a natural defense against DNA damage.

Making a Difference... Research for a Cure

Expenditures



To succeed in finding a cure for cancer, NFCR recognizes that planning and choosing the right strategies are crucial. That is why we make sure that we invest our research dollars wisely where we can make the biggest impact in the shortest amount of time.

NFCR is supported by caring individuals around the world who donate to our ongoing cancer research programs—programs that are saving lives. In order to win the battle against this devastating disease, it is critical that we have the means available to fund new and innovative research opportunities.


There are several different ways to help contribute. One way is to contribute to NFCR's cancer research programs with a gift of cash. You can mail a contribution or make a donation online at www.NFCR.org/Donate. NFCR gladly accepts personal checks and most major credit cards. If you would like to make your gift in Honor or Memory of someone, we'd be happy to help you.

Depending on your philanthropic goals and financial situation, certain types of gifts may be better for you. NFCR offers several suggestions about creative giving options, such as:

- Annuity gifts that guarantee lifetime payments you can never outlive
- Gifts that offer significant tax savings such as the donation of a timeshare, a house or other property
- Wills and Bequests to leave a lasting legacy
- Gifts of land in return for payments for life
- Gifts to take care of loved ones
- Grants from Family Foundations
- Corporate Employee Matching where your gift could double



Revenues



If you would like to consider ways to help defeat cancer, please call 1-800-321-CURE (2873) and ask to speak to one of our Planned Giving Officers. We're happy to help!

For over 32 years, NFCR has achieved the highest standards of accountability to our donors, friends, and scientists. We meet the standards of the Better Business Bureau's Wise Giving Alliance and the Federal Combined Campaigns and our stewardship of your donations ensures that your donation goes to cancer research and prevention that is saving lives.



Dr. Curt Civin contributes to *Cancer Immunotherapy* by exploring the immune system responses to malignant tumors.



Dr. Danny Welch discovers metastasis suppressor genes, *KiSS1* and *BRMS1*, creating a new group of drug to stop the spread of cancer.



Dr. Phyllis Bowen validates that lycopenes prevent or delay the progression of prostate cancer.



One Family's Effort to "Wipe Out" Cancer

If you have seen the 1964 classic surfing movie, *The Endless Summer*, then you have seen Wayne Miyata. Wayne was one of the first surfers to be filmed doing a successful "tube ride" through a large wave. The footage was taken at Ala Moana in Oahu, Hawaii in the early 1960s, and was included in the movie, *The Endless Summer*. Throughout the years Wayne Miyata became legendary in surfing circles. A native Hawaiian, Wayne was known by many surfers around the world for his fine hand-crafted surfboards. He was an expert in the old-style techniques of pinlining and glossing boards — adding color and decoration using resin. Most mass-produced surfboards use airbrushing for color and designs, but Wayne did it all by hand.

Wayne passed away in 2005 after battling esophageal cancer. In looking for a way to honor Wayne and help fight this disease, his daughter Tava established an NFCR Rose Fund. A Rose Fund is a permanent Fund that is set up as a lasting tribute to someone special. Everyone who wants to honor a friend or loved one, or their memory can make a contribution to the Fund. As the Fund grows — enabling NFCR to continue vital research — it becomes a lasting tribute to them and their life. Many of Wayne's family, friends, and fans have contributed to the Wayne Miyata Rose Fund.

Less well known than lung cancer, but no less serious, esophageal cancer starts in the inner layer of the esophagus, the 10-inch long tube that connects the throat and stomach. The most common symptom is difficulty swallowing and a sensation of food sticking in your throat or chest. Esophageal cancer strikes many people including the actor Humphrey Bogart, who died of esophageal cancer at age 57. In Bogart's day, the outlook for people with esophageal cancer was poor. But today survival rates have increased, in part because of the work by NFCR scientists around the world who are closing in on cures for not only esophageal cancer, but all types of cancers.

Wayne's memory lives on in surfing communities around the world and the Wayne Miyata Rose Fund continues to fund *Research for a Cure*.

"My father, Wayne Miyata, was a unique and colorful person that enjoyed life to the very fullest. He was an international surfing champion receiving recognition in the 1960's surfing film classic, "The Endless Summer" executing "the perfect tube ride." He was a true craftsman and artist in surfboard manufacturing. He was also a mentor to many in the surfing industry and has received heart-warming posthumous tributes from his many friends and other surfing legends.


"For me, he was a wonderful father who taught me to surf, took me water sliding with his surf buddies when I was a kid, and went to the California Speedway for NASCAR weekends. We had a true friendship and I miss him dearly.

"We all wish that we could have seen the early signs of the esophageal cancer that took my father's life too soon. The trouble was that he was incorrectly diagnosed with acid reflux approximately seven months before his Stage 4 cancer diagnosis. With early detection, he might have had time to fight the battle against cancer and win."

—Tava Miyata, daughter of Wayne Miyata



"On any day of the year it is summer somewhere in the world..."



Dr. Graham Richards, supported by the NFCR, Intel and United Devices, launches Screensaver-Lifesaver project to screen potential leukemia treatments.



Dr. Yung-Chi Cheng develops PHY906, a Chinese herbal medicine formula, which decreases toxicities in colorectal and lung cancer drugs.



Dr. Martyn Smith discovers the effectiveness of kelp, a natural plant product, which reduces high estrogen levels in breast cancer patients.

Financials

National Foundation for Cancer Research, Inc. and Affiliates Consolidated Statement of Financial Position September 30, 2005

Assets:

Cash and Cash Equivalents	\$1,212,780
Accounts Receivable	248,352
Bequests Receivable	123,500
Prepaid Expenses and Other Assets	426,092
Amounts Held in Trust by Others	1,765,302
Furniture and Equipment, Net of Accumulated Depreciation	269,600
Investments	7,951,410
Total Assets	<u>\$11,997,036</u>

Liabilities:

Accounts Payable and Other Liabilities	\$677,157
Research Contracts Payable	1,240,054
Accrued Compensation and Benefits	127,485
Deferred Revenue	9,845
Total Liabilities	<u>\$2,054,541</u>

Net Assets:

Unrestricted	
Designated for Research	\$5,852,176
Undesignated	884,312
Total Unrestricted Net Assets	<u>\$6,736,488</u>
Temporarily Restricted	1,683,441
Permanently Restricted	1,522,566
Total Net Assets	<u>\$9,942,495</u>
Total Liabilities and Net Assets	<u>\$11,997,036</u>

To receive a copy of NFCR's Financial Statements and Schedule for September 30, 2005 (with Independent Auditor's Report) from the auditing firm of KPMG, please call us at 1-800-321-CURE or go to our website, www.NFCR.org.



Dr. Susan Band Horwitz uses natural analogues of Taxol, a widely used chemotherapy drug, to prevent cancer cell's resistance to anti-cancer drug.



Dr. Wayne Marasco provides high quality sFv to isolate antibodies to develop cancer research tools and therapeutic agents to treat cancer.



Dr. Graham Richards' Screensaver-Lifesaver project has over 2.4 million individual computer users participating worldwide and has analyzed over 3.5 billion molecules.

Financials

National Foundation for Cancer Research, Inc. and Affiliates Consolidated Statement of Activities Year Ended September 30, 2005

Revenues, Gains and Other Support:

Public Support	\$12,224,600
Bequests	1,472,888
Mailing List Rentals	518,738
Net Investment Income	771,552
Change in Value of Split-interest Agreements	79,256
Other Revenue	75,219
Total Revenues, Gains, and Other Support	<u>\$15,142,253</u>

Expenses:

Program Services:	
Research	
Cancer	3,421,818
Genetic Diseases	970,997
Public Education and Information	5,692,118
Total Program Services	<u>\$10,084,933</u>
Supporting Services:	
Fund-raising	\$4,177,731
Management and General	851,635
Total Supporting Services	<u>\$5,029,366</u>
Total Expenses	<u>\$15,114,299</u>
Changes in Net Assets	<u>27,954</u>

Net Assets, Beginning of Year	<u>9,914,541</u>
Net Assets, End of Year	<u>\$9,942,495</u>



Dr. Danny Welch discovers CRSP3, a gene which has contributed to the development of drugs that prevent or inhibit the spread of cancer.



Drs. Daniel Von Hoff and Laurence Hurley develops the DPC4 minus cell model, which treats pancreatic cancer.



Dr. Esther Chang develops a liposome-based drug delivery system for breast cancer, a potential first-line of defense against breast cancer.



Drs. Daniel Von Hoff and Laurence Hurley DPC4 minus cell model enters into clinical trial.

2005

The National Foundation for Cancer Research 2005 Donor Report

Throughout this Progress Report, you have read about the work we are doing to cure the world of cancer. Whether it's a researcher like Dr. Esther Chang pioneering a new way to deliver anti-cancer drugs directly to a tumor, or Dr. Michael Sporn who is discovering new methods of treating leukemia, none of this work would be possible without the generous support of our contributors.

Legacy and Estate Gifts

We honor and thank the following supporters who have provided for our work in the future by including the National Foundation for Cancer Research in their wills, trusts or other estate plans, or through charitable gift annuities, charitable remainder trusts or charitable lead trusts.

List of FY 2005 Estate Gifts

Estate of A. Matthew Barbera
Estate of Eleanor S. Bailey
Estate of Paul Baron
Estate of Marti Aberson Boden
Estate of Helen Hall Boothman
Estate of Margaret M. Borkholm
Estate of Sylvia Foster Bowen
Estate of Dora Letitia Sayers Caro
Estate of Bernice S. Cohen
Estate of Myrtle E. Crawford
Estate of Mary Clark
Roane Downing
Estate of Benjamin & Alice Fisch
Estate of Evajean
Houghtaling Foster
Estate of Charles Donald Garrett
Estate of Steven V. Good
Estate of Rocco A. Grappone
Estate of Eleanor L. Hart
Estate of Elsa Heidere
Estate of Eugenia Hyland
Estate of Carl Kendrick
Estate of DeNard B. Kirk
Estate of Edith C. Lovell
Estate of Giselle McCulloch
Estate of Claire T. Mellman
Estate of Kathryn Mesick
Estate of Grace O'Hare
Estate of Emma Phillips
Estate of Ethel A. Pierson

Estate of Rosalind K. Roth
Estate of Marjorie Schoch
Estate of Esther E. Siltanen
Estate of Margaret Sommer
Estate of Elizabeth Jane Stephenson
Estate of Iona Bailey Walton
Estate of Dorothy R. Watson
Estate of George C. Wernham

List of FY 2005 Trust Gifts

Trust of Preston & Beth Belcher
Trust of James Childs
Trust of Grace W. Densmore
Trust of Conway Wing & Gertrude Finck Dickson
Trust of Mildred R. Dumbauld
Trust of Lillian L. Everett
Trust of Mary W. Grimwade
Trust of Wilbur C. Grosse
Trust of John T. Holowiak
Trust of Leonard & Eustelle Hudson
Trust of Edward Low
Trust of Susan Mahn
Trust of Joslyn Moffitt Perkins
Trust of Albert L. & Eleanor R. Repecka
Trust of Louis C. Sachs
Trust of Grace E. Spelman
Trust of Mabel Taylor

Individuals, Fiscal Year 2005

The National Foundation for Cancer Research values dedicated individuals who make our work possible. We thank everyone, particularly our generous individual donors and Challis Society members listed below, who provided financial assistance to support our *Research for a Cure*. (October 1, 2004 – September 30, 2005)

Amina R. Allaudin, M.D., P.A.	Mrs. Carole Cavanaugh-Fettig
Ms. Kathleen Allen	Mr. Alfred Chamizo
Mrs. Mary Anderson-Rowland	Joseph & Helena Chan
Ms. Karen Angel	Mr. Glen Charles
Mr. Lee A. Anis	Richard & Pamela Chemelli
Dr. Walter E. App	William & Barbara Claus
Mr. & Mrs. Leonard Ascosi	Ms. Shelley Cohen
Mr. Gordon W. Ashley	Mr. Stephen Collela
Mr. John Baechle	Mrs. Lois De Conca
Ms. Gertrude J. Bailey	Ms. Carol L. Cook
Mr. Elliot A. Baines	Ms. Nancy Cook
Mr. Allan Baker	David & Cheryl Copham
Ms. Judy Barnhard	Mr. & Mrs. Frank R. Cordon
Mr. Robert Beck	Dr. John J. Costanzi
Ms. Susan R. Blalock	Ms. Judith M. Coulter
Ms. Helen C. Bones	Ms. Lynn S. Couri
Annie Bridges	Ms. Marilyn Marie Cupp
Richard & Marie Brisette	Ms. Joyce E. Dakis
Mr. John Brown	Ms. Pauline K. Dall
Ms. Julie A. Brown	Mr. & Mrs. Thomas C. Davey
Ms. Rebekah Scott Bryan	Mr. Richard K. De Poe
Ms. Mary M. Burden	Mr. & Mrs. Joseph M. Desarla
Mr. Jack W. Burkart	Mr. & Mrs. Sean M. Downey
Ms. Loretta C. Cain	Thomas & Jennifer Dudley
Mr. Steve Callas	Ms. Catherine W. Dukehart
Mr. Ugo Campello	Mrs. Wenqi Dwyer
Luis Benito & Erica Campos	Mrs. Sally Dyer
Mr. Alejandro Capo	Mrs. Pat J. Eberhardt
Mr. & Mrs. John C. Carruth	Mrs. Betty A. Eberle
Ms. Nancy J. Casey	Mr. Richard D. Ennen
Mrs. Alice Catalyne	Mr. & Mrs. Edward R. Evans

The National Foundation for Cancer Research

2005 Donor Report (continued)

Mr. Russell Evans	Mrs. Lee Hunter	Mr. & Mrs. William C. McCormick	Ms. Elaine G. Cook
Mr. Alejandro Fernandez	Mr. David Hutchings	Mr. Robert McCrea	Dr. Eva Reyes
Mr. Hector Ferral	Ms. Marie D. Hutchinson	Ms. Laura L. McDonald	Mr. & Mrs. Donald R. Reynolds
Mr. Robert G. Finnigan	Mr. David G. Ives	Mr. Thomas McDonough	Ms. Ann G. P. Rhodes
Mr. Elmo L. Fischer	Mr. Jerry E. Jageman	Mr. & Mrs. Stephen E. McGrath	Mr. Milton V. Richards
Ms. Diane B. Fixler	Ann Johnson	Mr. & Mrs. Thomas E. McGrath	Mr. Stephen Richards
Mr. & Mrs. David Flynn	Mr. & Mrs. James Johnson	Mr. David E. McKee	Mr. Peter H. Robinsohn
Mr. Patrick J. Foley	Jerry & Nancy Johnson	Ms. Caridad Mejusto	Mrs. Willie Mae Robinson
Mr. & Mrs. Dave Gadd	Scott & Beatrice Johnson	Jill & Gary Meltzer	Ms. Shirley A. Rodriguez
Maria Gerst	Mrs. Martha Jones	Ms. Maria Mendoza	Mr. & Mrs. Brent Rosenthal
Mr. Edmund Goodlow	Mr. & Mrs. Phillip Jones	Mr. John Mengelos	Mr. Peter Roskowitz &
Mr. Robert B. Gordon	Mr. Luke Kay	Ms. Debra Michel	Mr. Karl White
Mr. Gregory S. Goss	Mrs. Ethel E. Kessler	Mr. & Mrs. W. R. Miller	Michael Rothkopf
Carol & Arthur Graham	Edward & Jeanette Kimbrough	Mr. & Mrs. Ward M. Miller, Jr.	Ms. Elizabeth M. Ruffin
Ms. Barbara Graham-Palmore	Mr. Terry P. Kinskey	Mr. Ronald S. Monroe	Franklin C. Salisbury, Jr. &
Mr. & Mrs. Jay M. Grossman	Mr. & Mrs. A. H. Kozlowski	Ms. Susan L. Morrow	Sujuan Ba
Ms. Eleanor N. Hahn	Mr. Howard A. Kuehner	Ms. Janet Myruski	Mr. Jerome J. Sauer
Mr. & Mrs. Roderick V. Hamel	Mr. Delbert E. Laehn	Mr. Carey S. Nachenberg	Robert & Antoinette Seay
Jeffrey & Deborah Hamer	Mr. W. R. Lake, Jr.	Mrs. Lillian R. Neff	Mr. John Sebert, Jr.
Mr. & Mrs. Michael A. Hamilton	Ms. Elizabeth W. Lamond	Mr. & Mrs. Mike Neigoff	Ms. Edith L. Sennet
Mr. Robert T. Hanlon	Mr. Neil L. Langberg &	Mr. Mark C. Nicholson	Anne-Marie Serre
Mr. & Mrs. Norman Hardee	Mrs. Nancy A. Linn	James Nicol	Mr. Gregory Shaia
Mr. Everette P. Hardy	Mrs. Edna Larocque	Mr. & Mrs. James R. Nolan	Ms. Gwen Sharp
Audrey Harris Harvey	Mr. Vito M. Lastella	Dr. & Mrs. Carlos Ochoa	Mr. & Mrs. Arthur C. Sheffield
Bruce & Barbara Hayman	Mr. & Mrs. David R. Latchford	Mrs. Ruth H. O'Dea	Mr. Lewis R. Shields
Ms. Monika Henderson	Ms. Ann M. Layden	Mr. Edward Ohlbaum	Mr. Mace Siegel
Bryan & Bethany Hensley	Richard & Jean Lee	Lee & Connie Olmstead	Mr. Peter M. Singer
Mr. Keith Hess	Ms. Loren Levine	Ms. Rebecca Duren O'Neill	Donald & Mary Karlene Skolak
Mr. Frank Hewitt	Mr. & Mrs. Steve Lewis	Mr. & Mrs. Thomas F. Orr	Patricia S. Smith
Ms. Rosalie J. Hickerson	Ms. Jeanette Lowe	Ms. Mary Osborne	Christopher Lloyd &
Ms. Jan Hier-King	Dr. Henry S. Lowenhaupt	Mr. Joseph H. Parker	Arleen Sorkin
Mrs. Lilly H. Hiller	Mr. Francesco A. Lucarelli	Carol Holland Parlette	Mr. Charles H. Spaulding
Mr. & Mrs. Richard Hoffman	Ms. Janice Lwin	Ms. Linda J. Pierret	Mr. Geoffrey W. D. Spratt
Mr. & Mrs. Donald Holland	Mr. Neil P. Lynch	Mr. Harold Poole	Dr. Raghavakaimal Sreekumar
Ms. Patricia L. Holman	Mr. David Maas	Michael & Deborah Poor	Mr. & Mrs. Craig Stanford
Mr. & Mrs. Rory Hood	Vance & Barbara Mainquist	Mr. & Mrs. Murray Popper	Mr. Robert W. Stark
Ms. Susan L. Hook	Mr. Richard Mallery	Ms. Darla Postil	Ms. Susan B. Stearns
Dr. Susan B. Horwitz	Ms. Regina L. Mandabach	Ms. Rosalyn Preston	Mr. & Mrs. A. Emmet
Joe & Misti Howie	Mr. Michael B. Mann	Mr. Robert Provence	Stephenson, Jr.
Mrs. Howard Huizinga	Mr. & Mrs. Martin Marlowe	Gerald & Barbara Ranzal	Ms. June W. Stoner
Mr. Danny Humphreys	Ms. Coleen M. McCormick	Mr. Saimi L. Reed &	Mrs. Charlotte R. Strobl
			Arthur & Sheila Strosberg

The National Foundation for Cancer Research

2005 Donor Report *(continued)*

Mr. & Mrs. James R Sullivan, Jr.
Mr. David Sum
Mr. & Mrs. Joel Sussman
Mrs. Helen Szczech
Mr. & Mrs. Haruka Takano
Ms. Margaretta Taylor
Mr. David B. Thomas
Mr. David S. Thomas
Mr. Richard M. Thomas
Joan E. Thornton, M.D.
Mr. & Mrs. John M. Trani
Mr. & Mrs. Wayne Underhill
Mr. & Mrs. David S. Vanderhooft
Mr. Vincent D. Virga
Dr. & Mrs. Daniel D. Von Hoff
Mr. Myles E. Walsh
Ronald & Nena Walsh
Ms. Ann M. Warren
Ms. Deborah Weiss
Danny R. Welch

Earnie & Deb Welch
August Ochabauer & Janet Welcome
Ms. Gloria A. Welter
Mrs. Patricia Wentz
Mrs. Catherine S. West
Edith M. White
Mr. Jim Wilczek
Mr. & Mrs. James Williamson
Mr. Thomas J. Wilson
Ms. Patricia A. Wincovitch
Ms. Barbara Lee Winterfeld
Mr. & Mrs. Steve Wrench
Ms. Betsy R. Wright
Mr. Walter Wurster
Clinton & Virginia Yates
Mrs. Carolyn Young
Mr. & Mrs. Arthur Zuch
Mr. X. Kembo Zunzanyika

Shipp Family Foundation
Tamkin Foundation
The Bellini Foundation
The Esseff Foundation
The Hornthal Family Foundation
Title Family Foundation

Connecticut

Andre & Elaine Suan Foundation
Robert & Lynn Zimmer Foundation
William H. Prusoff Foundation

District of Columbia

The I Do Foundation

Florida

Abraham Tober & Anna Tober Foundation
Anna & Nathan Flax Foundation
Charitable Foundation
Diane & James Perrella Family Foundation
George Barrie Foundation
Jewish Charity & Elderly Housing Fund
Leo J. & Celia Carlin Fund
Mathew & Josephine Birnbaum Foundation
Norman & Vivian Weiden Foundation
PricewaterhouseCoopers LLP
Samuel E. & Mary W. Thatcher Foundation
Simon & Sylvia Zisman Foundation
Talpalar Family Foundation
The Alvin & Fern Davis Foundation
The Avellino Family Foundation
The Edwards Foundation
The Greenburg-May Foundation
The Mary Elizabeth Ewing Foundation
Werner Foundation

Georgia

Elaine & Joseph Italiaander Fund of Jewish Communal Fund
Lakeland Villa Patient's Fund
The Scharff Foundation

Iowa

Thomson Charitable Foundation

Illinois

Azulay Family Foundation
Churchill Family Foundation
Franciscan Sisters of Sacred Heart
Joseph H. Goldberg Private Foundation
MNR Foundation
Rhoda & Henry Frank Family Foundation
Sharon & Robert Simons Family Foundation
Sidney & Jacqueline Hess Philanthropic Fund of Jewish Federation of Metro Chicago
The Dolores Bowers Charitable Fund
Ziegler Charitable Foundation

Kansas

Jana E. Pinker Memorial Foundation

Maryland

David B. & Shirley L. Sykes Foundation
Lowell & Harriet Glazer Family Foundation
The Friel Foundation

Massachusetts

Abraham Zaleznik Family Charitable Fund
Sara F. Clark Fund of Berkshire Taconic Community Foundation
The William H. Reisner Foundation
Michigan
Loraine & Ben Maibach Foundation

Foundation Support

The National Foundation for Cancer Research receives tremendous financial support from foundations across America. Some of those listed have been around for many years, others have just been created in the last decade. And they all have one thing in common: a desire to rid the world of cancer. NFCR wishes to thank all of these foundations for their generous support.

Alabama

The Jurenko Foundation

Arizona

Sam & Gerry Ward Foundation

California

Alex & Ruth Britton Philanthropic Fund of Jewish Federation Foundation
B Y Foundation
Charles & Jeanne Shaw Fund of Tri-Valley Community Foundation CA
Cloverlane Foundation

David & Carole Schultz Family Foundation
Glenn & Mary Ann Charles Family Foundation
Ira & Joanne Kirshbaum Family Foundation
John V. Gomes Foundation
Leo & Gertrude Marantz Fund of Jewish Community Foundation
Mindlin Family Foundation
Pat Boone Foundation
Prostate Cancer Foundation
Robert & Lillie Breitbard Foundation

The National Foundation for Cancer Research

2005 Donor Report (continued)

Samuel & Jean Frankel
Foundation
The Whiting Foundation

Minnesota

Mildred J. Pike Charitable Fund

Missouri

Pearson Family Foundation

Nevada

Crystal Family Foundation

New Hampshire

Sidney H. Rabinowitz
Family Foundation

New Jersey

Allegra & Isaac Franco
Foundation
Hopewell Hospice Foundation
of America
Paragano Family Foundation
Steidlitz Hotchkiss Family Fund of
Ayco Charitable Foundation
The MAM-NWJ Foundation

New York

Americans We Are A
Family Foundation
Charles B. Israel Foundation
Doreen & Gilbert Bassin
Family Foundation
Elias & Harriet M.
Wollerstein Foundation
Empire State Carpenters Funds
Gusti Brandt Foundation
Ira M. Resnick Foundation
Joseph Rosen Foundation
Marilyn & Marshall Butler
Foundation
Muriel & Felix Lilienthal
Foundation
Robert & Roslyn Smith
Foundation
Schon Family Foundation
Shirley W. & William L.
Griffin Foundation

Sol & Hilda Furst Foundation
Stewart & Sherry Kahn Fund of
Jewish Communal Fund
The Dabah Family Foundation
The Elena Melius Foundation
The Gluckman Foundation
The Kandell Fund
The Marilyn & Stanley
Cohen Foundation
The Myron M. Studner
Foundation
The Poznanski Family Foundation

North Carolina

Grover & Jane McNair
Charitable Foundation
Wiegand Family Foundation

Ohio

Barbara Quint Levy Philanthropic
Fund of Jewish Community
Federation of Cleveland
Ronald & Shirley Parsons Fund of
Dayton Foundation Depository

Oklahoma

Morris & Libby Singer Foundation

Pennsylvania

Avery Foundation
Harvey Rosalie Goldberg
Private Foundation
Mario & Sara Rafalin Foundation
McCrudden Family Foundation
Tess Clayton Charitable Foundation

Rhode Island

Emitom Watson Foundation
Trinity Church
South Carolina
The Greenville District Fund

Tennessee

Fraser Family Fund of
Community Foundation
of Greater Memphis

Texas

Austin Community Foundation
Clements Foundation
Holloway Family Foundation
Joseph & Helen Swiff Memorial
Fund of Dallas Jewish
Community Foundation
Sally & Bernard Fuchs
Charitable Foundation

Utah

Benjamin & Sophie Scher
Charitable Foundation

Virginia

Earl D. Leader Charitable
Foundation
The Perry Family Fund of Ayco
Charitable Foundation

Washington

G. Gary & L. Marie Duskin D. A.
Fund of WSU Foundation

Wisconsin

Chapman Foundation

Corporate Support

The National Foundation for Cancer Research is grateful for the support it has received from corporations.

Alaniz, LLC
Aria Communications Corp
Calmark Corporation
Cenveo
ColorTree, Inc.
Concord Litho Group
CP Direct
Elm Cross Associates LLC
EuroMotorcars
Helen Galland Associates
Hub Labels, Inc.
Inno-Pak, Inc.
James Wutke Painting
Japs-Olson Company
Joy A. Wallace Revokable Trust
Karchner Logistics & Distribution
Landcraft, Inc.
Legg Mason, Inc.
List Services Corporation
Long & Foster Real Estate, Inc.
LSI America Corporation
M B Duncan Inc.

M Hamilton Physical Therapy PC
Merck Partnership For Giving
Merkle Direct Marketing, Inc.
Novartis
N W P L, Inc.
Olcott Consulting Group
Pence Holdings, Inc.
Pharmaceutical Research &
Manufacturers of America
Pine River Ranch
PricewaterhouseCoopers
Riggs Bank NA
Silverton Construction Account
Snyder Realty Advisors LLC
Specialized Mailing Services
St Mary Land &
Exploration Company
The M&T Charitable Foundation
Vocus, Inc.
Wachovia Corporation
YM BioSciences Inc.

1st row, from left to right: NFCR Donor Brian Ostry; NFCR Planned Giving Officers Elana Lipka and Liz Diamond; and NFCR Supporters Nick and Sienna Turecamo.

2nd row, from left to right: NFCR Supporter Pete Reisinger, NFCR Advisory Board Member Jamie Farr, and NFCR President Franklin C. Salisbury, Jr.; NFCR Fellow Dr. Yung-Chi Cheng; NFCR Center for Metastasis Research Director, Dr. Danny Welch.

3rd row, from left to right: NFCR Donor Elizabeth Netting; NFCR Donor Bob Carlson; and NFCR Donors, Lou Barletta, Mayor of Hazleton, PA and Harold Karchner, Chairman, Hazleton Golf Tournament.

4th row, from left to right: NFCR Donors Don Mills and Harriet LaClaire; NFCR Board of Directors, Dr. Padmakumar Kaimal; and NFCR Donor Jerry Bleeker.



NFCR Management Team

Franklin C. Salisbury, Jr.

President

Sujuan Ba, Ph.D.

Chief Operating Officer

Chief Science Officer

Yi Michael Wang, M.D., Ph.D.

Vice President of Science

Silas Deane

Vice President of Communications

NFCR Board of Directors

Chairman

John Slye, Ph.D.

Slye-Hughes International, LLC

Virginia

Mark Baran

Vice President

Neuberger Berman, LLC

New York

Kevin Connolly

Vice President

Bank of New York

New York

Padmakumar Kaimal, Ph.D.

Vice President

Suven Life Sciences

New Jersey

Lorie Karnath

International Managing Director

Rescentris

Berlin, Germany

NFCR Advisory Board

Jamie Farr

Actor

California

Abraham Amoros

Chief of Communications

Office of the Governor

Pennsylvania

Pamela Carter

Executive Vice President

Fleetguard, Inc.

Tennessee

David Chew

Chief Executive Officer

Minimatics, Inc.

California

William Haseltine, Ph.D.

Former President & CEO

Human Genome Sciences, Inc.

Maryland

Richard Mallery, Esq.

Managing Partner

Snell & Wilner, LLC

Arizona

Ted Peters, Ph.D.

Interim President

Pacific Lutheran Theological Seminary

California

William Potter

President

Robert R. Merideth, Inc.

New York

Beverly Sauer, Ph.D.

Professor of Business Communication

Johns Hopkins University

Washington, DC



National Foundation for Cancer Research

4600 East West Highway

Suite 525

Bethesda, Maryland 20814

1-800-321-CURE (2873)

www.NFCR.org